The histamine H 3 receptor (H 3 R) is a promising target in the development of new compounds for the treatment of mainly centrally occurring diseases. However, emerging novel therapeutic concepts have been introduced and some indications in the H 3 R field, e.g. migraine, pain or allergic rhinitis, might take advantage of peripherally acting ligands. In this work, kojic acid-derived structural elements were inserted into a well established H 3 R antagonist/inverse agonist scaffold to investigate the bioisosteric potential of g-pyranones with respect to the different moieties of the H 3 R pharmacophore. The most affine compounds showed receptor binding in the low nanomolar concentration range. Evaluation and comparison of kojic acid-containing ligands and their corresponding phenyl analogues (3-7) revealed that the newly integrated scaffold greatly influences chemical properties (S Log P, topological polar surface area (tPSA)) and hence, potentially modifies the pharmacokinetic profile of the different derivatives. Benzyl-1-(4-(3-(piperidin-1-yl) propoxy)phenyl)methanamine ligands 3 and 4 belong to the centrally acting diamine-based class of H 3 R antagonist/inverse agonist, whereas kojic acid analogues 6 and 7 might act peripherally. The latter compounds state promising lead structures in the development of H 3 R ligands with a modified profile of action.
Regular Article
Histamine is one of the most important chemical messengers in the human (h) organism. It mediates its pleiotropic effects via four known G protein-coupled receptors (GPCR), the histamine receptors (H 1 R-H 4 R). H 1 R and H 2 R are mainly associated with the development of allergy and ulcer, respectively, and the corresponding antagonists have reached blockbuster status in the therapy of these widespread diseases.
1) The youngest member of the histamine receptor family, H 4 R, is involved in inflammatory processes and takes an immunomodulatory role. The first ligands are currently evaluated in an early stage of clinical studies.
2) The H 3 R takes an exceptional role as an auto-and heteroreceptor that is mainly but not exclusively expressed in the central nervous system (CNS). It controls the synthesis and liberation of the endogenous ligand histamine and hence, regulates its concentration in the synaptic cleft. Located on non-histaminergic neurons, the H 3 R modulates the release of various other neurotransmitters and neuropeptides.
3) By keeping a certain neurotransmitter balance in brain compartments with co-localized neurons the H 3 R ensures different physiological functions like vigilance, learning, attention, or feeding behaviour. In the peripheral nervous system (PNS) the receptor influences e.g. nerve and C fibers involved in the regulation of sympathetic effector systems and pain sensation, respectively. Antagonists/inverse agonists of the H 3 R are able to increase the neurotransmitter content and may find their application in the therapy of cognitive diseases, sleep/wake disorders, epilepsy, obesity, pain or allergic rhinitis. Several substances are progressing in clinical trials. 4, 5) H 3 R antagonists/inverse agonists ( Fig. 1 ) follow a general structural blueprint consisting of a basic moiety coupled via an alkyl spacer to a central core. This element constitutes a hydrogen bond acceptor, which in most cases is connected to an aromatic ring system, and might be substituted with a variety of polar, lipophilic, basic or acidic moieties or their combination. 6) Whereas the amino-alkyl-acceptor fragment is required as basic pharmacophore to interact with the western part of the H 3 R binding pocket, the target allows for broader variation in the eastern part of the molecule. A second basic moiety usually boosts H 3 R affinity as has been shown with many compounds of the class of diamine-based ligands. [7] [8] [9] Computational models support an additional ionic interaction with transmembrane domain 5. 10, 11) However, due to the strong receptor binding and their lipophilicity diamine-based ligands tend to accumulate centrally, which as a result might induce severe side effects and/or phospholipidosis. 12) One aim of this study was to establish new lead structures that combine the second basic centre with increased hydrophilicity to avoid potentially occurring side effects in an early state of compound development.
Due to high polarity and electron density g-pyranone derivatives were tested as substitutes of the different elements in the H 3 R pharmacophore. Kojic acid, 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one, served as starting point for the preparation of a series of H 3 R ligands. This interesting scaffold was first isolated from various fungi strains, e.g. Penicillum, Gluconoacetobacter and especially Aspergillus oryzae, that is commonly called koji in Japanese. Koji malt has been used in the production of sake or soya sauce for a long time. A broad field of application is found in food and cosmetic industries. Due to its antioxidant properties it is used to decolourize food or as depigmenting agent. The latter is supported by a strong inhibitory effect on the pigment-generating enzyme tyrosinase. [13] [14] [15] For chemical purposes kojic acid consists of a 4H-pyran-4-one scaffold that is substituted with a hydroxyl and a hydroxymethyl group in positions C-3 and C-5, respectively. The resulting enol moiety exhibits a pK a value of 7.9-8.0 allowing for similar reactions as described for phenols. Kojic acid is a chelating agent that enables bidentate complexes with various metals that have been reported as radical scavengers (Fig. 2) . [16] [17] [18] Physicochemical properties of kojic acid and its application in consumer goods emphasize the safety of this scaffold.
The goal of this work was to combine the H 3 R antagonist/ inverse agonist pharmacophore with kojic acid-derived elements by integrated and spacer approaches to take advantage of the physicochemical and pharmacological properties of the g-pyranone scaffold and to modify the pharmacokinetic properties of an existing H 3 R pharmacophore.
Chemistry Precursors containing the 1-(3-phenoxypropyl)piperidine pharmacophore were prepared as described before. 9, 19, 20) Briefly, piperidine was alkylated with 3-chloropropan-1-ol under basic conditions (Chart 1). The resulting alcohol precursor P1 was chlorinated (P2) and subsequently transferred to phenol ether synthesis. Precursor compounds P3 and P5 as well as final compounds 1 and 2 were prepared by applying Williamson-like conditions combined with a Finkelstein exchange. 21, 22) Derivatization of ester P3 and nitrile P5 led to carboxylic acid P4 and benzyl amine P6, respectively. 23) Hence, a series of precursor compounds consisting of the H 3 R affine pharmacophore but differing functional moieties was designed as a molecular toolbox. Amine precursor P6 was the starting point in the preparation of diamine-based ligands. Benzyl amines 3 and 4 were prepared in a one-pot approach by reductive amination of benzaldehyde using sodium triacetoxyborohydride as reducing agent. 24) Kojic acid (P7) was functionalized to obtain a variety of gpyranone-containing precursors (Charts 2, 3). Benzyl kojic acid P8 was synthesized under basic conditions using highboiling solvents (cesium carbonate in anhydrous N,N-dimethylformamide (DMF) (a) 25) and soda lye in methanol (b), 26, 27) respectively). Although side processes like ringopening of the vinylogous lactone caused by the attack of the aqueous alkali solution were expected, 28) yields ranged between 50% and 60% in both approaches. Method (b) resulted to be the more practicable one due to faster purification. Precursor P9 was prepared by chlorination in pure thionyl chloride resulting in 75% conversion to the product. 29) The addition of solvents like toluene to improve a usually quantitative reaction minimized yields even further. P9 was subsequently reduced using zinc/hydrochloric acid to obtain the methyl derivative P10. 30) Benzyl kojic acid P8 was treated with acid P4 in a Mitsunobu reaction 31) giving compound 5. Diamine-containing compounds 6-8 were obtained by nucleophilic substitution of chlorokojic acid P9. Secondary amines 6 and 8 were synthesized in tetrahydrofuran (THF) at ambient temperature, whereas stronger conditions were required for the quantitative conversion into the tertiary amine 7. Microwave irradiation of the reagents in DMF led to the desired product formation. Purification, especially of the diamine-based compounds, by column chromatography had to occur under harsh conditions. Due to the high polarity of the compounds equivoluminous mixtures of methylene chloride and ammoniacal methanol were regularly used. Compounds were usually crystallized as salts of oxalic acid. Polarity and hydrophilicity frequently resulted in the enclosure of water requiring repeated re-crystallization steps, which minimized overall reaction yields.
Williamson-like conditions, as described before, were applied to get methyl derivative 9. In contrast, the synthesis of compounds 10 and 11 as well as the corresponding precursors P11 and P12 was realized starting from kojic acid (P7) due to a more convenient preparation and higher overall yields (Chart 3). After alkylation of the enol moiety of P7 Vol. 58, No. 10 the resulting 3-chloropropoxy derivative P11 was substituted with piperidine to obtain a H 3 R pharmacophore-like scaffold with exchanged central core (10) . The hydroxymethyl group of 10 was subsequently chlorinated (P12) and coupled with piperidine resulting in a diamine-containing final compound (11) . First approaches to insert the two piperidine moieties in one step by applying the activated dialcohol 3-(6-((methylsulfonyloxy)methyl)-4-oxo-4H-pyran-3-yloxy)propyl methanesulfonate failed due to compound polymerization.
Pharmacology All final compounds 1-11 as well as reference inverse agonists thioperamide 32) and pitolisant (formerly known as BF2.649 or tiprolisant) 33) (cf. Fig. 1 ) were evaluated with regard to their hH 3 R affinity using a membrane preparation from HEK-293 cells stably expressing hH 3 R. In a competition binding assay the displacement of [ 
H]N
a -methylhistamine by the respective test compound was determined. 33, 34) Thioperamide and pitolisant exhibited hH 3 R affinities in the nanomolar concentration range (pK i ϭ7.1 and 7.9, respectively), which is in accordance with results from other experiments. 33, [35] [36] [37] The antagonist/inverse agonist efficacy of the 1-(3-phenoxypropyl)piperidine scaffold was proven in several investigations of different research groups, including ours.
38)
Results and Discussion 1-(3-Phenoxypropyl)piperidine (1) is the receptor-binding domain of many H 3 R antagonists/inverse agonists and incorporates the most important structural elements that ensure receptor interactions, namely the tertiary amine and in a certain distance a polar moiety coupled to an aryl group. In the [ 
H]N
a -MeHA displacement assay 1 showed moderate hH 3 R affinity (pK i ϭ6.6; Table 1 ). Affinity was slightly improved by insertion of the benzylic hydroxyl group in compound 2 (pK i ϭ6.9). The flexible benzyl amine 3 combines lipophilic with hydrogen bond donor properties of a second basic moiety in the eastern molecule part leading to a highly affine compound with binding strength in the low nanomolar concentration range (pK i ϭ8.6). The trisubstituted analogue 4 maintained affinity in the nanomolar concentration range (pK i ϭ7.1) showing comparable receptor binding to thioperamide. Probably, affinity differences between 3 and 4 result from the improved accessibility of the second basic moiety in compound 3, whereas the tertiary amine in ligand 4 is sterically shielded by the benzyl rests.
Kojic acid derivatives were inserted into the pharmacophoric blueprint of H 3 R ligands aiming at the substitution of either the benzyl moieties of compounds 3 and 4 in the eastern molecule part or the central phenoxy core of the pharmacophore 1. In a first attempt, kojic acid was coupled to carboxylic acid P4 and benzyl amine P6, respectively, resulting in compounds 5-7. g-Pyranone analogues of compounds 3 and 4, the diamines 6 and 7, exhibited good hH 3 R affinities in the nanomolar concentration range (pK i ϭ7.5 and 8.0, respectively) indicating that the hH 3 R binding pocket accepts these highly polar and electron withdrawing moieties in the eastern part of the ligand. The binding strength of the disubstituted derivative 7 is comparable to that of reference inverse agonist pitolisant. Compared to its phenyl analogue 4 compound 7 showed improved affinity (Fig. 3A) . This may be caused by additional polar interactions. Lipophilic, nonaromatic residues with fixed points of high electron density, as seen in benzyl ester 5, were also well tolerated (pK i ϭ7.5). 
S Log P Surprisingly, this compound exhibited receptor binding in the same range as diamine 6 did indicating that p interactions evoked by the benzyl residue in 5 compensate ionic interactions resulting from the second basic moiety in 6. A smaller diamine-based ligand was designed with compound 8. However, probably due to the missing hydrogen bond acceptor or p donor in the central core of the ligand this approach led to a pronounced loss of receptor binding (pK i ϭ4.3).
The direct implementation of kojic acid instead of the central phenyl ring of pharmacophore 1 was realized with compounds 9-11. Related scaffold-hopping approaches were followed by several research groups aiming at the discovery of new leads or at the differentiation of the pharmacodynamic properties of H 3 R ligands (cf. Fig. 1 ). Abbott chemists focused on the rigidification of the phenoxy core (e.g. ABT-239), 39, 40) whereas researchers from Glaxo Smith Kline (GSK) published an 'inverse' aromatic core (e.g. GSK 189254). 41) Scientists at Novo Nordisk increased anti-obesity efficacy by using urea and cinnamic amide moieties as central elements (e.g. NNC 38-1202). 42, 43) Comparable functionalities had already been used in imidazole-containing ligands like thioperamide or clobenpropit and derivatives. 44, 45) The advanced clinical candidate, pitolisant, contains an alkyl ether core. 33) However, the application of this strategy, i.e. the direct implementation of kojic acid derivatives, did not succeed: compound 11 showed weak receptor binding in the submicromolar concentration range (pK i ϭ6.2), whereas 9 and 10 hardly exhibited hH 3 R affinity (pK i ϭ5.0 and 4.7, respectively). The comparison between affinities of pyran-4-ones 10 and 11 and the corresponding phenyl-substituted ligands 2 and JNJ-5207852, 37, 46) respectively, is diagrammed in Fig. 3B . Results clearly show the limitations of kojic acid derivatives as bioisosteric phenyl substitutes. Whereas kojic acid-derived moieties as central core hardly show receptor interactions, they are well accepted as extension of the eastern molecule part resulting in ligands with affinities in the low nanomolar concentration range. Receptor binding strength of compounds 6 and 7 is comparable to that of phenyl-derived ligands 3 and 4.
In a first approximation of a compound's drug-likeness Lipinski's rule of five considering size, number of donor and acceptor groups and lipophilicity of a ligand is frequently applied. 47) Extended guidelines include e.g. molar refractivity 48) and the topological polar surface area (tPSA) as helpful parameters to assess drug transport properties. 49) The size of the most affine compounds 3-7 and the arrangement of donor and acceptor systems are in accordance with the general rules. Physicochemical parameters calculated to evaluate the CNS accessibility of these ligands are shown in Table 1 . The calculated chemical properties indicate that phenyl derivatives 3 and 4 but not g-pyranones 5-7 are able to pass the BBB. Hence, the newly designed kojic acid derivatives offer new perspectives for the development of H 3 R ligands with a modified pharmacokinetic and pharmacodynamic profile. At least partially peripherally acting H 3 R antagonists/inverse agonists could be effective in the therapy of different states of pain, obesity, or allergic rhinitis. 53) Clinical studies (phase II for allergic rhinitis) 54) of compounds like the H 3 R antagonist PF-3654746 55) or the dual acting H 1 R/H 3 R antagonist GSK-1004723 5) corroborate this approach.
Despite an ambitious synthetic procedure the preparation of a series of kojic acid derivatives (5-11) was successfully realized. Additionally, for reasons of comparison and evaluation, the corresponding phenyl analogues were prepared (1-4). Kojic acid as a scaffold was for the first time associated with H 3 R medicinal chemistry. It was integrated into a well established H 3 R antagonist/inverse agonist pharmacophore showing possibilities and limitations of kojic acid derivatives as bioisosters of the different phenyl moieties existent in compounds 3 and 4. The comparison of H 3 R affinities and calculated chemical properties of ligands 3 and 4 with those of compounds 6 and 7 indicates that the scaffold modification allows for a new pharmacokinetic profile within the class of diamine-based H 3 R antagonist/inverse agonists and might determine the site of action. A comparable approach that was recently performed with lipophilic sandwich complex-containing residues resulted in the design of centrally acting H 3 R pharmacological tools. 56) In contrast, kojic acid derivatives 6 and 7 represent novel lead compounds offering promising possibilities for the development of peripherally acting H 3 R antagonist/inverse agonists.
Experimental
Chemistry. General Remarks Reagents and solvents were commercially obtained from Merck, Sigma-Aldrich and ABCR. Melting points were determined on a Büchi 510 melting point apparatus (Büchi, Switzerland) and are uncorrected.
1 H-NMR spectra were recorded on a Bruker AMX 300 (300 MHz) spectrometer (Bruker, Germany).
1 H-NMR data are reported in the following order: chemical shift (d) in ppm downfield from tetramethylsilane as internal reference; multiplicity (br, broad; s, singlet; d, doublet; dd, double doublet; t, triplet; m, multiplet; q, quintet); approximate coupling constants (J) in Hertz (Hz). 13 C-NMR spectra were recorded on a Bruker AC 200 (50 MHz) spectrometer (Bruker, Germany); all peaks resulted to be singlets. Electrospray ionization (ESI)
Reaction yields were not optimized and refer to the pure final products, which in most cases were crystallized as salts.
3-(Piperidin-1-yl)propan-1-ol Hydrochloride (P1) 9, 19, 20) Piperidine (51.1 g, 0.6 mol), 3-chloropropan-1-ol (47.3 g, 0.5 mol), potassium carbonate (74.3 g, 0.75 mol) and potassium iodide (8.3 g, 0.05 mol) were refluxed in absolute acetone (300 ml) during 72 h. The mixture was allowed to cool to room temperature, inorganic components were removed by filtration and the filtrate was concentrated to dryness. Purification of the crude oil was achieved by means of distillation (20 mbar, 95°C). The oily product was crystallized as hydrochloride from 2-propanol (white solid, 54.6 g, 79% 1-(3-Chloropropyl)piperidine Hydrochloride (P2) 9, 19, 20) Alcohol P1 (13.4 g, 0.08 mol) was suspended in toluene (100 ml). Under inert atmosphere and at 0°C an excess of thionyl chloride (11.6 ml, 0.16 mol) was added dropwise. Once the exothermic reaction had decayed the mixture was stirred for 3 h at 60°C. Upon completion of the reaction thionyl chloride and toluene were distilled off. The crude product was re-crystallized from ethanol (beige solid, 14.8 g, quantitative conversion). Methyl 4-(3-(Piperidin-1-yl)propoxy)benzoate (P3) 9, 20) Chloride P2 (3.0 g, 15.1 mmol), methyl 4-hydroxybenzoate (2.6 g, 16.8 mmol), potassium carbonate (9.0 g, 90.6 mmol) and potassium iodide (2.5 g, 15.1 mmol) were refluxed in absolute acetone (100 ml) during 3 d. The crude was taken up in soda lye (2 N) and purified as described for compound P3. The resulting product was a brown oil (2.6 g, 61% 
4-(3-(Piperidin-1-yl)propoxy)benzoic Acid (P4)

23)
Ester P3 (2.0 g, 7.2 mmol) was dissolved in a mixture of THF (8 ml) and methanol (8 ml); potassium hydroxide pellets (1.2 g, 21.6 mmol) were dissolved in water (16 ml). Both solutions were transferred into a sealed vial and heated in the microwave oven for 15 min at 70°C. After cooling the organic solvents were removed under reduced pressure and the aqueous solution neutralized with hydrochloric acid (10 N). Reaching the isoelectric point of the product (close to neutral pH value) it crystallized as a white solid (1.9 g, quantitative conversion). 9, 20) Chloride P2 (3.0 g, 15.1 mmol), 4-hydroxybenzonitrile (2.0 g, 16.8 mmol), potassium carbonate (9.0 g, 90.6 mmol) and potassium iodide (2.5 g, 15.1 mmol) were refluxed in absolute acetone (100 ml) during 3 d. After cooling the inorganic salts were filtered off and the filtrate was concentrated under reduced pressure. The remaining residue was taken up in soda lye (5 N) and extracted with methylene chloride. The combined organic extracts were washed with brine and dried over magnesium sulphate. The organic solvent was removed under reduced pressure. The product was obtained as yellowish oil (1.7 g, 47%) . Chloride P2 (2.2 g, 11.1 mmol), phenol (1.2 g, 12.2 mmol), potassium carbonate (9.2 g, 66.6 mmol) and potassium iodide (1.8 g, 11.1 mmol) were refluxed in absolute acetone (100 ml) during 3 d. The crude was purified as described for compound P3. The resulting yellow oil was crystallized as oxalic salt from ethanol (1.6 g, 47% (4-(3-(Piperidin-1-yl)propoxy)phenyl)methanol Hydrochloride (2) 9, 20) Chloride P2 (2.1 g, 10.5 mmol), 4-hydroxybenzyl alcohol (2.6 g, 21.0 mmol), potassium carbonate (8.7 g, 63.0 mmol) and potassium iodide (1.7 g, 10.5 mmol) were refluxed in absolute acetone (100 ml) during 2 d. After purification (as described for compound P3) the resulting light solid was crystallized as hydrochloride from 2-propanol (1.5 g, 50% 24) Under inert atmosphere at ambient temperature benzaldehyde (0.6 g, 6.0 mmol) and amine P6 (1.0 g, 4.0 mmol) were coupled in 1,2-dichloroethane (DCE) (20 ml) for 3 h. The resulting imine was reduced with sodium triacetoxyborohydride (1.3 g, 6.0 mmol) during 30 min of stirring. The reaction was quenched by adding a saturated solution of sodium carbonate. The product was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulphate, filtered and concentrated under reduced pressure. Further purification was carried out by column chromatography (methylene chloride : ammoniacal methanolϭ9.8 : 0.2→ 9.5 : 0.5). Two fractions were eluted. Both colourless oils were crystallized as salts of maleic and oxalic acid, respectively, resulting in white solids after re-crystallization (3: 0.3 g, 20.5%; 4: 0.02 g, 1%). Especially 4 had to be recrystallized several times from acetonitrile due to incorporation of water and stayed quite hygroscopic. 25) Under inert atmosphere kojic acid (P7, 5 g, 35.2 mmol), cesium carbonate (11.5 g, 35.2 mmol), and benzyl bromide (12.5 ml, 105 mmol) were suspended in absolute DMF (25 ml). The mixture was refluxed for 2 h. After cooling it was purified by dry load column chromatography (methylene chloride : ammoniacal methanolϭ9.5 : 0.5) giving a light brown solid (4.2 g, 52%) .
4-(3-(Piperidin-1-yl)propoxy)benzonitrile (P5)
Benzyl-1-(4-(3-(piperidin-1-yl)propoxy)phenyl)methanamine Ligands (3, 4)
N-Benzyl-1-(4-(3-(piperidin-1-yl)propoxy)phenyl)methanamine
5-(Benzyloxy)-2-(hydroxymethyl)-4H-pyran-4-one (P8) (a)
(b) 26, 27) Alternatively, a solution of P7 (5 g, 35.2 mmol) in methanol (40 ml) was added to a solution of sodium hydroxide (1.6 g, 38.7 mmol) in water (5 ml). This mixture was heated to reflux, benzyl bromide was added dropwise and reflux was continued for 12 h. The solution was allowed to cool to ambient temperature, the solvent removed by reduced pressure and the resulting brown solid was washed with water (15 ml) and methanol (10 ml). Re-crystallization in methanol led to beige crystal needles, which were collected by filtration (4.6 g, 57% (
5-(Benzyloxy)-4-oxo-4H-pyran-2-yl)methyl 4-(3-(Piperidin-1-yl)propoxy)benzoate Hydrogenoxalate (5)
31)
A solution of benzyl kojic acid P8 (0.56 g, 2.4 mmol) and triphenylphosphine (0.42 g, 1.6 mmol) in THF (5 ml) was added dropwise to another solution consisting of benzoic acid P4 (0.42 g, 1.6 mmol) and diethyl azodicarboxylate (DEAD) (0.28 g, 1.6 mmol) in THF (5 ml). Under inert atmosphere the mixture was stirred overnight at room temperature, filtered and purified by column chromatography (methylene chloride : ammoniacal methanolϭ9.5 : 0.5). The product is crystallized with oxalic acid in ethanol and re-crystallized twice in acetonitrile (0.035 g, 4% 29) Kojic acid (P7, 10 g, 70.4 mmol) was dissolved in thionyl chloride (40 ml) and stirred at room temperature for 1 h. The product crystallized during this time and was collected by filtration. The resulting residue was washed with petroleum ether and re-crystallized from water giving a beige solid (8.4 g, 75%) .
2-(Chloromethyl)-5-hydroxy-4H-pyran-4-one (P9)
Chemical Formula: C 6 H 5 ClO 3 . 2H, br s), 3.96-4.10 (6H, m), 6.51 (1H, s) 5-Hydroxy-2-methyl-4H-pyran-4-one (P10) 30) Chlorokojic acid P9 (1.0 g, 6.2 mmol) was suspended in water (5 ml) and heated to 50°C. Zinc powder (0.8 g, 12.45 mmol) and hydrochloric acid (2 ml) were added. Whereas the mixture was kept at 70°C for 3 h, the solids mostly dissolved. After hot filtration the product was extracted with methylene chloride. The combined organic extracts were dried over sodium sulphate and evaporated to dryness. The crude was re-crystallized from 2-propanol affording a white solid (0.24 g, 31% 2-Methyl-5-(3-(piperidin-1-yl)propoxy)-4H-pyran-4-one Hydrogenoxalate (9) Methyl derivative P10 (0.23 g, 1.8 mmol), chloride P2 (1.8 g, 9.0 mmol), cesium carbonate (2.9 g, 9.0 mmol) and potassium iodide (0.3 g, 1.8 mmol) were heated in DMF for 2 h. The crude product was purified by means of column chromatography (methylene chloride : ammoniacal methanolϭ9.5 : 0.5→9.0 : 1.0) and crystallized with oxalic acid in ethanol. Re-crystallization of the beige solid was performed in acetonitrile (0.064 g, 11% 2 mmol) were suspended in absolute DMF (100 ml). 1-Bromo-3-chloropropane (17.3 ml, 176 mmol) was added via dropping funnel. After refluxing (110°C) the mixture for 2 h it was allowed to cool to room temperature, filtered, and the dark brown solution was concentrated. The residue was dissolved in methylene chloride (100 ml) and concentrated on silica gel to be submitted to dry load column chromatography (methylene chloride : ammoniacal methanolϭ9.5 : 0.5). The product was evaporated to dryness to give an orange solid (5.5 g, 72% 5-(3-(piperidin-1-yl) propoxy)-4H-pyran-4-one Hydrogenoxalate (10) Chloride P11 (2 g, 9.2 mmol), piperidine (1.1 ml, 11 mmol), potassium carbonate (1.9 g, 13.8 mmol) and potassium iodide (0.15 g, 0.9 mmol) were heated in absolute acetone (20 ml) for 2 h and stirred overnight at room temperature. After cooling, filtration and concentration steps the crude was purified by column chromatography (methylene chloride : ammoniacal methanolϭ9.5 : 0.5). 0.2 g of the isolated brown oil (0.66 g, 27%) were crystallized with oxalic acid in ethanol and re-crystallized from acetonitrile (beige solid, 0.4 g, 12% 
5-(3-(Piperidin-1-yl)propoxy)-2-(piperidin-1-ylmethyl)-4H-pyran-4-one (11)
Chloride P12 (0.3 g, 0.93 mmol), piperidine (0.14 ml, 1.4 mmol), potassium carbonate (0.64 g, 4.7 mmol) and potassium iodide (0.16 g, 0.93 mmol) were refluxed in absolute acetone (20 ml) for 8 h. After filtration of the inorganic salts and concentration of the filtrate the remaining residue was dissolved in soda lye (2 N) and the product extracted with methylene chloride. The resulting oil was purified by column chromatography (methylene chloride : ammoniacal methanolϭ9.0 : 1.0) and crystallization with oxalic acid. The white solid was re-crystallized in acetonitrile (0.015 g, 3% 33) Before starting experiments cell membranes were thawed, homogenized by sonication at 4°C and kept in ice-cold binding buffer (12.5 mM MgCl 2 , 100 mM NaCl and 75 mM Tris/HCl, pH 7.4). Competition binding experiments were carried out as follows: membranes (20-25 mg/well in a final volume of 0.2 ml binding buffer) were incubated with [ 3 H]N a -MeHA (2 nM; 85 Ci/mmol) and different concentrations of test ligand. Assays were run at least in duplicates with seven appropriate concentrations between 0.01 nM and 100 mM of the test compound. Incubations were performed for 90 min at 25°C and shaking at 250 rpm. Non-specific binding was determined in the presence of 10 mM unlabelled HA. In saturation binding experiments the maximal binding concentration (B max ) was found to be 0.89 pmol · mg Ϫ1 and the K d value of [ 3 H]N a -MeHA resulted to be 2.98 nmol · l Ϫ1 (pK d ϭ8.53Ϯ0.01). The bound radioligand was separated from free radioligand by filtration through GF/B filters pre-treated with 0.3% (m/v) polyethyleneimine using an Inotech cell harvester. Unbound radioligand was removed by three washing steps with 0.3 ml/well of ice-cold 50 mM Tris-HCl buffer, pH 7.4, containing 120 mM NaCl. The filters were soaked in a 9 ml scintillator and counted using a PerkinElmer MicroBeta ® Trilux scintillation counter. Competition binding data were analyzed by the software GraphPad Prism 3.02 using non-linear least squares fit. Affinity values (K i ) were expressed as meanϮstandard deviation (S.D.). K i values were calculated from the IC 50 values according to the Cheng-Prusoff equation. 57) 
